KRAS and cancer: Clinical data on LAC patients revealed that, when PD-1 inhibitors had been employed to diagnose people with KRAS, TP53, or KRAS/TP53-mutated cancer, the PD-L1 development in tumors, as in the TP53/KRAS co-mutation groups, was elevated, and the percentage of CD8+ T cells in the TME was significantly high [112].